Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients

Abstract EN

Background.

Butyrylcholinesterase (BChE) is synthesized mainly in the liver and an important marker in many infectious/inflammatory diseases, but its role in acquired immunodeficiency syndrome (AIDS) patients is not clear.

We wished to ascertain if BChE level is associated with the progression/prognosis of AIDS patients.

Methods.

BChE levels (in U/L) were measured in 505 patients; <4500 was defined as “low” and ≥4500 as “normal.” Associations between BChE level and CD4 count, WHO stage, body mass index (BMI), C-reactive protein (CRP) level, and duration of hospitalization were assessed.

Kaplan–Meier curves and Cox proportional hazards model were used to assess associations between low BChE levels and mortality, after adjustment for age, CD4 count, WHO stage, and laboratory parameters.

Results.

A total of 129 patients (25.5%) had a lower BChE level.

BChE was closely associated with CD4 count, WHO stage, CRP level, and BMI (all P<0.001).

Eighty-four patients (16.6%) died in the first year of follow-up.

One-year survival was 64.5 ± 4.5% for patients with low BChE and 87.6 ± 1.8% for those with normal BChE (log-rank, P<0.001).

After adjustment for sex, age, BMI, WHO stage, and CD4 count, as well as serum levels of hemoglobin, sodium, and albumin, the hazard ratio was 1.8 (95% confidence interval, 1.0–3.2) for patients with a low BChE compared with those with a normal BChE (P=0.035).

Conclusion.

BChE level is associated with HIV/AIDS severity and is an independent risk factor for increased mortality in AIDS patients.